{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:57:30Z","timestamp":1783699050763,"version":"3.55.0"},"reference-count":21,"publisher":"Japan Endocrine Society","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1507\/endocrj.ej25-0089","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T22:07:21Z","timestamp":1756418841000},"page":"1309-1316","source":"Crossref","is-referenced-by-count":2,"title":["Blood steroid hormone profile and clinical outcomes following switching from metyrapone to osilodrostat in patients with Cushing disease"],"prefix":"10.1507","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8510-345X","authenticated-orcid":false,"given":"Kei","family":"Yokozeki","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Hokkaido 060-8638, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1870-6688","authenticated-orcid":false,"given":"Hiraku","family":"Kameda","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Hokkaido 060-8638, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aika","family":"Miya","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Hokkaido 060-8638, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Forensic Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Hokkaido 060-8638, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Matoba","sequence":"additional","affiliation":[{"name":"Department of Forensic Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Hokkaido 060-8638, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinobu","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Hokkaido 060-8638, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Atsumi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Hokkaido 060-8638, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Pivonello R, De Martino MC, De Leo M, Lombardi G, Colao A (2008) Cushing\u2019s syndrome. Endocrinol Metab Clin North Am 37: 135\u2013149.","DOI":"10.1016\/j.ecl.2007.10.010"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Nieman LK, Biller BM, Findling JW, Murad MH, Newell-Price J, et al. (2015) Treatment of Cushing\u2019s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 100: 2807\u20132831.","DOI":"10.1210\/jc.2015-1818"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Pivonello R, Ferrigno R, De Martino MC, Simeoli C, Di Paola N, et al. (2020) Medical treatment of Cushing\u2019s disease: an overview of the current and recent clinical trials. Front Endocrinol (Lausanne) 11: 648.","DOI":"10.3389\/fendo.2020.00648"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Pivonello R, De Leo M, Cozzolino A, Colao A (2015) The treatment of Cushing\u2019s disease. Endocr Rev 36: 385\u2013486.","DOI":"10.1210\/er.2013-1048"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Fleseriu M, Pivonello R, Young J, Hamrahian AH, Molitch ME, et al. (2016) Osilodrostat, a potent oral 11\u03b2-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing\u2019s disease. Pituitary 19: 138\u2013148.","DOI":"10.1007\/s11102-015-0692-z"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Bertagna X, Pivonello R, Fleseriu M, Zhang Y, Robinson P, et al. (2014) LCI699, a potent 11\u03b2-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing\u2019s disease: results from a multicenter, proof-of-concept study. J Clin Endocrinol Metab 99: 1375\u20131383.","DOI":"10.1210\/jc.2013-2117"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Armani S, Ting L, Sauter N, Darstein C, Tripathi AP, et al. (2017) Drug interaction potential of osilodrostat (LCI699) based on its effect on the pharmacokinetics of probe drugs of cytochrome P450 enzymes in healthy adults. Clin Drug Investig 37: 465\u2013472.","DOI":"10.1007\/s40261-017-0497-0"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Andersen K, Hartman D, Peppard T, Hermann D, Van Ess P, et al. (2012) The effects of aldosterone synthase inhibition on aldosterone and cortisol in patients with hypertension: a phase II, randomized, double-blind, placebo-controlled, multicenter study. J Clin Hypertens (Greenwich) 14: 580\u2013587.","DOI":"10.1111\/j.1751-7176.2012.00667.x"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Amar L, Azizi M, Menard J, Peyrard S, Watson C, et al. (2010) Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism. Hypertension 56: 831\u2013838.","DOI":"10.1161\/HYPERTENSIONAHA.110.157271"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Bonnet-Serrano F, Poirier J, Vaczlavik A, Laguillier-Morizot C, Blanchet B, et al. (2022) Differences in the spectrum of steroidogenic enzyme inhibition between Osilodrostat and Metyrapone in ACTH-dependent Cushing syndrome patients. Eur J Endocrinol 187: 315\u2013322.","DOI":"10.1530\/EJE-22-0208"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Jin S, Wada N, Takahashi Y, Hui SP, Sakurai T, et al. (2013) Quantification of urinary 18-hydroxycortisol using LC-MS\/MS. Ann Clin Biochem 50: 450\u2013456.","DOI":"10.1177\/0004563213476272"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Honda A, Yamashita K, Miyazaki H, Shirai M, Ikegami T, et al. (2008) Highly sensitive analysis of sterol profiles in human serum by LC-ESI-MS\/MS. J Lipid Res 49: 2063\u20132073.","DOI":"10.1194\/jlr.D800017-JLR200"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Hirtz R, Libuda L, Hinney A, F\u00f6cker M, B\u00fchlmeier J, et al. (2022) The adrenal steroid profile in adolescent depression: a valuable bio-readout? Transl Psychiatry 12: 255.","DOI":"10.1038\/s41398-022-01966-2"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Dormoy A, Haissaguerre M, Vitellius G, Do Cao C, Geslot A, et al. (2023) Efficacy and safety of Osilodrostat in paraneoplastic Cushing syndrome: a real-world multicenter study in France. J Clin Endocrinol Metab 108: 1475\u20131487.","DOI":"10.1210\/clinem\/dgac691"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Prabhu MK, Kishore S, Mohamed Akram Ali S, Rajamohamed H, Nepolean R (2020) Comparison of the use of metyrapone and osilodrostat for Cushing disease: a systemic review. J Adv Pharm Pract 6: 12\u201324.","DOI":"10.46610\/JAPP.2024.v06i01.002"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Pivonello R, Fleseriu M, Newell-Price J, Bertagna X, Findling J, et al. (2020) Efficacy and safety of osilodrostat in patients with Cushing\u2019s disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase. Lancet Diabetes Endocrinol 8: 748\u2013761.","DOI":"10.1016\/S2213-8587(20)30240-0"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Gadelha M, Bex M, Feelders RA, Heaney AP, Auchus RJ, et al. (2022) Randomized trial of Osilodrostat for the treatment of Cushing disease. J Clin Endocrinol Metab 107: e2882\u2013e2895.","DOI":"10.1210\/clinem\/dgac178"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Detomas M, Altieri B, Deutschbein T, Fassnacht M, Dischinger U (2022) Metyrapone <i>versus<\/i> Osilodrostat in the short-term therapy of endogenous Cushing\u2019s syndrome: results from a single center cohort study. Front Endocrinol (Lausanne) 13: 903545.","DOI":"10.3389\/fendo.2022.903545"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Creemers SG, Feelders RA, de Jong FH, Franssen GJH, de Rijke YB, et al. (2019) Osilodrostat is a potential novel steroidogenesis inhibitor for the treatment of Cushing syndrome: an <i>in vitro<\/i> study. J Clin Endocrinol Metab 104: 3437\u20133449.","DOI":"10.1210\/jc.2019-00217"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Melau C, Riis ML, Nielsen JE, Perlman S, Lundvall L, et al. (2021) The effects of selected inhibitors on human fetal adrenal steroidogenesis differs under basal and ACTH-stimulated conditions. BMC Med 19: 204.","DOI":"10.1186\/s12916-021-02080-8"},{"key":"21","unstructured":"21  (2004) Metopirone (metyrapone) Prescribing Information Novartis Pharma AG https:\/\/wwwaccessdatafdagov\/drugsatfda_docs\/label\/2010\/012911s026lblpdf accessed on February 10, 2025."}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/72\/12\/72_EJ25-0089\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T03:38:07Z","timestamp":1764992287000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/72\/12\/72_EJ25-0089\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej25-0089","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"EJ25-0089"}}